Skeletal morbidity secondary to metastases and osteoporosis is common in patients with advanced prostate cancer. Despite the typically sclerotic nature of prostate cancer metastases, osteoclast mediated osteolysis may play a significant role. This review addresses the newly recognised antitumour effects of bisphosphonates in addition to their role in inhibiting osteoclast mediated bone resorption. Both preclinical and clinical evidence of a role for bisphosphonates in the treatment and prevention of bone metastases secondary to prostate cancer is assessed.
Introduction
In 1998 prostate cancer was the most commonly registered new malignant diagnosis and the second most commonly registered cause of cancer related death amongst men in southeast England. 1 At the time of diagnosis approximately one quarter of men with prostate cancer will have distant metastases 2 and around 90% of these individuals will have bone involvement. 3 Treatment of the prostate cancer patient with bony metastasis is primarily palliative. Approximately 80% of men with bony metastases will have symptomatic improvement with androgen deprivation alone, 4 however, once primary hormonal therapy has failed the response to any further hormonal or cytotoxic therapy is poor. 5 Skeletal complications such as vertebral collapse, spinal cord compression and pathological fractures are common in patients with hormone refractory disease with bone loss being a major contributory factor. 6 This review focuses on the interaction of prostate cancer with bone and the potential role of bisphosphonates in the treatment and prevention of metastatic prostate cancer.
Bisphosphonates
Bisphosphonates are potent inhibitors of osteoclastic bone resorption. They are analogues of endogenous pyrophosphate in which the oxygen bridge has been replaced by a carbon atom. The addition of different carbon side chains has generated a diverse group of compounds based on a geminal bisphosphonate structure ( Figure 1 ). The R I side-chain is usually a hydroxyl group but the R II side-chain varies considerably and accounts for the widely differing potencies of these compounds. 7 Bisphosphonates rapidly disappear from the circulation. 8 This is due to the strong binding of these compounds to exposed hydroxyapatite crystals of bone. 9 This binding to bone forms the basis for the use of these compounds as skeletal markers in nuclear medicine when linked to 99 m-Technetium. In humans, the skeletal half-life of various bisphosphonates can be very long. 10 This is demonstrated by the fact that inhibition of bone resorption by bisphosphonates in the treatment of Paget's disease of bone can last for several years after treatment has stopped. Once bisphosphonates are bound to the skeleton they will be released only when bone is destroyed in the course of turnover or metastatic erosion. Indeed, bisphosphonates are selectively located on the bone surface in the resorption space where their local concentrations may reach several hundred micromolar. 11 As recently described, the action of bisphosphonates on bone can be considered at tissue, cellular and molecular levels. 12 At the tissue level the principal action of all bisphosphonates is to decrease bone turnover. There is good evidence that the first step in this process is a reduction in bone resorption as shown by a reduction in the level of urinary excretion of bone resorption markers such as cross-linked collagen peptides containing pyridinoline. 13 Decreased bone formation is secondary to inhibition of resorption and reflects reduced bone remodelling. Bisphosphonates do not directly suppress bone formation. 14 At the cellular level the principal site of action of bisphosphonates in normal bone is the osteoclast. In vitro and in vivo evidence supports at least four ways in which bisphosphonates can inhibit osteoclast activity: inhibition of osteoclast formation and recruitment; inhibition of osteoclast activation; inhibition of activity of mature osteoclasts and reduction in osteoclast lifespan by induction of apoptosis. 15 At the molecular level the definitive molecular targets responsible for bisphosphonate inhibition of osteoclastic bone resorption are beginning to be identified but it is possible that not all bisphosphonates act via the same mechanism. 7 
Pathophysiology of bone metastases in prostate cancer
Bone is the most favoured site of metastatic spread in prostate cancer. In adults normal bone is being continually remodelled under the influence of systemic hormones and local bone derived growth factors. The rich milieu of cytokines and growth factors in bone matrix provide a favourable site for seeding of metastasis from circulating tumour cells. 16 Metastatic bone lesions can interfere with normal bone homeostasis by causing the abnormal release of cytokines and growth factors that can alter the bone microenvironment. The seeding and growth of metastatic bone lesions is in part due to activation of normal bone cells. The normal process of bone remodelling is altered by the presence of tumour resulting in increased bone resorption and/or increased bone formation. 16 Cancer metastasizing to bone often causes bone destruction or osteolysis. There is substantial evidence to show that the increased bone resorption in bone metastases is mainly osteoclast mediated and locally activated by tumour but is not mediated by cancer cells themselves. Histomorphometric measurements of bone biopsy specimens from patients with metastatic breast cancer have shown that the number of osteoclasts is significantly increased in bone immediately adjacent to tumour as well as within metastases. 17 Parathyroid hormone related protein (PTHrP) is a major factor responsible for osteoclast mediated bone resorption at the site of bone metastases. Its expression is far more common in bone metastases than in metastases at other sites and is positively correlated to the presence of bone metastases and hypercalcaemia in patients with breast cancer. 16, 18 PTHrP is widely expressed in prostate cancer. 19 The molecular mechanisms by which tumour-produced PTHrP stimulates bone resorption have now been elucidated ( Figure 2 ). The osteoclast is a specialised macrophage whose differentiation is principally regulated by macrophage colony-stimulating factor (M-CSF), receptor activator of NFkB ligand (RANKL), and osteoprotegerin. 20 RANKL is secreted by osteoblasts and induces differentiation of osteoclast precursors by binding to its receptor, RANK located on osteoclast precursor cells. RANK and RANKL, together with M-CSF, are sufficient for osteoclastogenesis. 21 Osteoclast differentiation from precursor cells is blocked in a dose-dependent manner by recombinant osteoprotegerin and it has been shown that osteoprotegerin can bind to RANKL limiting its biological actions. 22 Cancer cells are unable to act as surrogate osteoblasts as they do not express RANKL and are therefore unable to directly stimulate osteoclastogenesis. 23 When MCF-7 breast cancer cells overexpressing PTHrP are added to co-cultures of murine osteoblasts and haemopoietic cells, osteoclast formation results without addition of any other osteotropic agents. 23 This suggests that cancer cells facilitate the lytic potential of osteoclasts via the action of cancer cell derived PTHrP on osteoblasts which causes the release of osteoclastogenic factors.
The enhancement of osteoclast numbers and activity in bone metastases results in pronounced osteolysis with the subsequent release of bone derived growth factors such as transforming growth factor b (TGFb). TGFb has been demonstrated to decrease RANKL mRNA and enhance osteoprotegerin mRNA levels in osteoblasts, a sequence of events that would be expected to limit osteoclastogenesis and aid remodelling in normal bone. 24 In bone containing metastatic cells, however, the microenvironment is changed and TGFb is capable of stimulating cancer cells to produce cytokines and growth factors that stimulate osteoclast activity. TGFb has been shown to significantly stimulate PTHrP expression in human breast cancer cells and to enhance secretion and stabilise mRNA for PTHrP in renal cell and squamous carcinoma. 16 TGFb may therefore be an important factor in the establishment and progression of cancer metastases to bone.
As prostate cancer is more frequently associated with sclerotic metastases, prostate cancer cells must possess properties different from those of other tumours commonly associated with lytic metastases. Sclerotic metastases are likely to be due to the production of soluble factors that can stimulate bone formation. A number of osteoblastic factors have been identified in prostate carcinoma tissue including Insulin-like growth factors, prostate specific antigen, fibroblast growth factor, bone morphogenic protein, urokinase-type plasminogen activator and endothelin-1. 16 Despite the osteoblastic tendencies in sclerotic metastases there is much evidence to suggest that osteolysis is a regular feature of prostate cancer bone disease. Indeed, osteolysis may be a necessary part of tumour invasiveness in bone.
Histological studies have shown that indices of bone resorption as well as bone-forming surfaces and active osteoblast numbers are increased in skeletal sites adjacent to metastatic prostate tumour tissue. 25 In a series of 78 iliac crest biopsies of patients with prostate cancer bone metastases, the fraction of eroded trabecular surfaces was consistently high and proportional to the severity of tumour invasion (lowest in tumour free bone, highest within metastases). 26 Eroded surfaces have been shown to be greatest within metastases but are associated with increased bone volume due to replacement of the existing trabecular tissue with abnormal woven bone, giving an overall appearance of sclerosis. 25 In vivo evidence exists showing the induction of osteolysis by prostate cancer. When the androgen insensitive prostate carcinoma cell line PC3 is injected intracardially into athymic male mice, an early response is the induction of osteolysis. These cells express known bone resorbing factors such as M-CSF and PTHrP. 27 Similar observations have been made following the systemic administration in nude mice of a breast carcinoma cell line that forms sclerotic metastases. The first event in this model is an increase in osteoclast mediated bone resorption followed by an increase in bone formation at the same site. 28 Evidence of osteoclastic activity in metastatic prostate cancer also comes from clinical studies. Increased biochemical indices of bone resorption are consistently found in patients with bone metastases. Ikeda et al showed that prostate carcinoma patients with active bone metastases had a higher urinary excretion of pyridinoline and deoxypyridinoline, specific markers of bone resorption, than did the patients with benign prostatic hyperplasica (BPH), patients with localised disease and patients with bone metastases well controlled with hormonal therapy. Urinary levels of these collagen breakdown products correlated with the extent of bone metastases. 29 Increased osteoblastic activity may be associated with increase osteoclastic activity in patients with metastatic prostate cancer. In one study, serum alkaline phosphatase activity was positively correlated to urinary hydroxyproline excretion suggesting an association between bone formation and resorption. 26 Taken together these observations indicate that osteolysis plays a crucial role in the appearance and growth of prostate cancer bone lesions. The classic sclerotic bone lesions seen in prostate cancer represent an uncoupling of normal bone resorption and deposition shifting the balance towards new matrix formation and mineralisation. The presence of osteoclastic bone resorption associated with prostate cancer bone metastasis provides the rationale for the use of bisphosphonates in the treatment of patients with advanced prostate cancer.
Direct effects of bisphosphonates on cancer cells
It is becoming clear that bisphosphonates have effects on cells other than the osteoclast. They may induce apoptosis in malignant cells in a similar way to that seen in osteoclasts and may interfere with the metastatic behaviour of tumours in bone.
Induction of apoptosis
There is now substantial evidence to show that bisphosphonates induce osteoclast apoptosis and similar effects have been observed in myeloma, breast and prostate cancer. Two reports by Hughes et al 30 and Selandoer et al 31 have demonstrated that bisphosphonates can cause osteoclast apoptosis both in vitro and in vivo. This results in a reduction of the osteoclast number on the bone surface and hence reduces osteoclastic resorption. At the molecular level there is increasing evidence to suggest that not all bisphosphonates have similar mechanisms of action and nitrogen-containing compounds (aminobisphosphonates) may excert different intracellular effects to the earlier, less potent bisphosphonates, such as clodronate. 7 Mammalian cells metabolise clodronate to a nonhydrolysable ATP analogue. 32 It is likely that any growth-inhibitory and cytotoxic effects of bisphosphonates such as clodronate is the result of cytoplasmic accumulation of these toxic metabolites that then compete with ATP in enzymatic reactions, ultimately resulting in cell death. Non-hydrolysable ATP analogues cannot, however, be detected in mammalian cells after 24 h treatment with aminobisphosphonates. 7 A different mechanism of action has recently been proposed for these drugs. Aminobisphosphonates may inhibit enzymes of the mevalonate pathway. The pathway of steroid biosynthesis from mevalonate results in the synthesis of farnesyl pyrophosphate and geranylgeranyl pyrophosphate. 33 These lipids are required for the post-translational modification (isoprenylation) of a number of important cellular proteins, such as laminins and small guanosine triphosphate binding proteins like Ras. These modifications are essential for cytoskeletal integrity and intracellular signalling by allowing these proteins to localise to the plasma membrane (Figure 3) . 34 Inhibition of the mevalonate pathway has been identified as a possible target for anticancer therapy. 35 Phenylacetate, a known farnesyl transferase inhibitor, inhibits protein isoprenylation including Ras farnesylation in LNCaP prostate cancer cells resulting in apoptosis in this cell line. 36 It now seems likely that aminobisphosphonates are capable of inducing apoptosis in a similar way. Studies in human myeloma and breast cancer cell lines have shown aminobisphosphonates can induce apoptosis. 37 -39 In both of these tumour types inhibition of the mevalonate pathway and prevention of protein prenylation occurs. 37, 40 Growth inhibitory effects of the aminobisphosphonates pamidronate and zoledronic acid on the prostate carcinoma cell lines LNCaP, PC3 and DU145 have previously been demonstrated 41 and zoledronic acid has been shown to induce apoptosis by inhibition of the mevalonate pathway in prostate cancer. 42 
Interruption of the metastatic cascade
Bisphosphonates have the ability to prevent tumour induced osteolysis and delay progression of metastases in rodent models of prostate cancer. 43, 44 Treatment with bisphosphonates suppressed and delayed the development of hind-leg paralysis in male Copenhagen rats using the intravenous injection of MLL tumour cells and concomitant caval vein clamping as a model for causing lumbar metastasis. Metastasis of tumour cells to bone is a complex cascade involving angiogenesis, loss of tumour cell adhesion, invasion of the vasculature, embolism, evasion of host defence, arrest at a distant site, extravasation and establishment of new growth. 16 There is preclinical evidence that bisphosphonates may interrupt this pathway in prostatic bone metastases at a number of points.
Angiogenesis
In order for a tumour to grow beyond a size of 1 -2 mm 3 and metastasise it must develop a new vascular network, angiogenesis is therefore an integral part of the metastatic cascade. Preliminary evidence suggests that bisphosphonates may have anti-angiogenic potential. Zoledronic acid, a new third generation aminobisphosphonate has been shown to inhibit proliferation and induce apoptosis in human umbilical vein endothelial cells in vitro. In a subcutaneous murine growth factor implant model, zoledronic acid dose-dependently inhibited the angiogenic response induced by fibroblast growth factor. 45 
Invasion
Tumour cell invasion may also be a target for bisphosphonate action. Boissier et al have demonstrated preincubation with bisphosphonates inhibits breast and prostate cancer cell line invasion in a matrigel invasion assay. Inhibition of invasion was through a specific action on tumour cells implying a pharmacological mechanism of action distinct from that on bone resorption. 46 Tumour cell invasion requires digestion of the basement membrane matrix by matrix metalloproteinases (MMPs) and these enzymes may also have a role in tumour mediated osteolysis. 47, 48 A possible mechanism by which bisphosphonates may affect invasion is via modulation of MMP activity. Two studies have shown that the bisphosphonates inhibit the proteolytic activity of MMPs 1,2,9, and 12. 46, 49 
Adhesion to bone
The localisation and subsequent growth of a tumour metastasis in the skeleton depends on the ability of tumour cells to adhere to specific ligands on endothelial cells, bone marrow stroma and the extracellular matrix. 48 Pre-treatment of two in vitro models of bone matrix with aminobisphosphonates has been shown to inhibit breast carcinoma tumour cell adhesion and spreading in a dosedependent manner (The non-nitrogen containing bisphosphonates, etidronate and clodronate, had no effect in this study). 50 Bossier et al further evaluated the direct effects of bisphosphonate treatment on the ability of prostate and breast cancer cells to adhere to unmineralised and mineralised bone matrices. Pre-treatment of these cells with bisphosphonates subsequently inhibited adhesion to bone matrices providing evidence for a direct cellular effect of bisphosphonates in preventing tumour cell adhesion to bone. 51 The bisphosphonates used in this study [ibandronate, NE-10244 (an analogue of risedronate), pamidronate and clodronate] did not exert any cytotoxic effects following 24 h treatment at concentrations used to inhibit tumour cell adhesion.
Bisphosphonates as a treatment of choice in prostate cancer
Preclinical studies indicate a potential role for bisphosphonates not only for the treatment, but also for the prevention of bone metastases due to prostate cancer. A number of trials have been conducted to investigate the clinical potential of bisphosphonate therapy. 
Bone pain
It is thought that tumour induced osteolysis is a major contributory factor causing bone pain in advanced cancer with skeletal metastasis. 16 Bisphosphonates have been shown to reduce pain in women with advanced breast cancer and clinically evident bone metastasis. 52 In an uncontrolled study in 1985 it was reported for the first time that treatment with intravenous clodronate induced sustained pain relief in and allowed mobilisation of some bedridden patients with advanced prostate cancer. 53 This was followed by a number of open studies showing reductions in pain in metastatic prostate cancer patients receiving i.v. clodronate. 54, 55 Unfortunately these results have not been supported by randomised trials of oral, 56 or i.v. followed by oral 57, 58 clodronate. These randomised trials failed to show a significant decrease in pain in the treatment groups, although all favoured clodronate treatment. Experience with other bisphosphonates, such as etidronate, 59 olpadronate 60 and pamidronate 61 -63 is similar. A single randomised, double-blind, placebo-controlled study of etidronate in 57 patients with painful bone metastasis due to prostate cancer again failed to show significant differences in symptom relief or analgesic needs. No meta-analysis has so far been performed.
The lack of efficacy of bisphosphonates in these randomised studies compared to studies in other malignancies is disappointing. There are a number of possible explanations. Studies of pain perception are notoriously difficult due to the large influence of subjective factors. Many of these studies were small and may have been of insufficient power to determine a significant difference in symptomatic improvement. The potency of the compounds, mode of administration and dose and duration of treatment may also all play a role.
Bone pain secondary to metastases has a complex aetiology and tumour induced osteolysis is not the only cause. Many other factors may also play a role. The pain in bone metastatic lesions may be partly due to immune responses. There is evidence indicating that inflammatory mediators, such as prostaglandins, can cause hyperalgesia in bone. Microfractures due to mechanical stress are also associated with bone pain, as are changes in intraosseous pressure. 64 Osteoporosis caused by androgen deprivation in patients with advanced prostate cancer may significantly contribute to bone pain and skeletal fracture. 65, 66 Bisphosphonates, due to their primary effect on the osteoclast, would not be expected to have an effect on these mechanical causes of bone pain.
Reduction of skeletal related events
Skeletal related events (SRE) are complications of metastatic disease and include pathological fractures, the need for radiation to bone or bone surgery, spinal cord compression and hypercalcaemia. A number of studies in other cancers have addressed the issue of attempting to limit skeletal morbidity with the prophylactic use of bisphosphonates once bony metastasis have been diagnosed. The results of two large, prospective randomised controlled trials in a total of 754 women with osteolytic metastasis secondary to breast cancer have recently been collated. Intravenous pamidronate (90 mg) three to four times weekly in addition to normal treatments significantly reduced skeletal morbidity. 67 A similar reduction in skeletal complications and improvement in quality of life has been reported in patients with multiple myeloma. 68 This issue has not yet been properly addressed in patients with prostate cancer although evidence is emerging. The MRC are currently conducting a phase III double-blind placebo controlled trial of oral clodronate in men with prostate cancer commencing or responding to standard hormonal treatment (Pr05). Three hundred and eleven patients had been randomised by July 1998 and preliminary results have been presented. 69 These results showed that oral sodium clodronate delayed progression to symptoms in prostate cancer. Novartis have undertaken a double-blind, multicenter randomised study of zoledronic acid (4 or 8 mg via infusion every 3 weeks) in men with hormone escape prostate cancer and a history of metastatic bone disease. Treatment with 4 mg led to a significant reduction in skeletal related events (mainly pathological fracture and radiation therapy to bone) at 15 months and a significant increase in the time to first skeletal related event. 70 There is anecdotal evidence suggesting a clinical antitumour effect of bisphosphonates in a case report of the reversal of paraplegia in a patient who was treated with clodronate and mithramycin. 71 In the original study by Adami, it was reported that treatment with intravenous clodronate allowed mobilisation of some bedridden patients as well as inducing sustained pain relief. 53 Despite these observations, to date no survival advantage of bisphosphonates in the treatment of patients with metastatic disease has been demonstrated although the newer more potent aminobisphosphonates have yet to be tested.
Bisphosphonates as adjuvant therapy
At present, treatment for metastatic bone disease and its associated complications is highly unsatisfactory and purely palliative. The idea of being able to carryout early prevention of bone disease, especially in patients at high risk of subsequent skeletal metastasis such as those with locally advanced prostate cancer, is therefore very appealing. Pre-clinical and clinical evidence reviewed here suggests that this may be a viable option in the future, especially with the newer, more potent aminobisphosphonates.
Three separate randomised placebo controlled trials of oral clodronate (1600 mg daily) in addition to standard adjuvant therapy in patients with early breast cancer have been inconsistent in their results. Diel et al have reported a 2-y study in 302 patients with stage 1 -3 breast cancer and micrometastatic bone marrow invasion. There was a significant difference in the incidence of bony metastases in the treatment group. 72 Similar results have been reported in abstract form in a larger study 73 but in the third, conflicting study in 299 patients showed no difference in the incidence of bone metastasis at 5 y. 74 The results of similar studies in prostate cancer are eagerly awaited. The MRC are running a further doubleblind placebo controlled trial to assess the possibility of using oral sodium clodronate over a 5-y period to delay time to symptomatic bone metastases in patients who have locally advanced, non-metastatic adenocarcinoma of the prostate (Pr04). Recruitment closed at the end of 1997 with 508 patients randomised. A similar placebocontrolled, multicenter, randomised trial by Novartis investigating zoledronic acid in the prevention of bone metastases in patients with biochemically recurrent prostate cancer who have rising PSA levels despite androgen deprivation (Protocol 704) is also underway.
Calcium homeostasis and prostate bone metastasis
Malignancy related hypercalcaemia is a serious metabolic disturbance associated with a number of cancers. The usual mechanism of this hypercalcaemia is an increased release of calcium from diseased bone although there may also be a humoral component via the actions of PTHrP on osteoclast activation. Intravenous fluid rehydration and bisphosphonate therapy is the standard treatment for severe, symptomatic hypercalcaemia. Symptomatic hypercalcaemia in men with metastatic prostate cancer is, however, uncommon. 75, 76 The low risk of hypercalcaemia in these men could be explained by the increase in osteoblastic activity in the majority of metastases preventing the release of calcium from bone. It has, however, been established in this article that there is a generalised increase in osteoclastic activity in these patients. Histological findings suggest that prostatic cancer induces generalised loss of trabecular bone with focal increased deposition in the metastases. 25 This situation may minimise disturbances in plasma calcium homeostasis but could also contribute to skeletal morbidity. It is also of interest to note that PSA cleavage of PTHrP can regulate the biological activity of this peptide, which may have a stabilising effect on potential malignant hypercalcaemia caused by this hormone. 19 In contrast to most malignancies, hypocalcaemia can be associated with metastatic prostate cancer. Hypocalcaemia is believed to be caused by calcium entrapment in bone as a consequence of excessive osteoblast activity in sclerotic metastasis. There have been a number of reports of low serum calcium levels 77, 78 and high PTH levels in patients with advanced prostate cancer. 79 Secondary hyperparathyroidism may occur frequently and may contribute to the generalised osteoclastic activity in patients with osteoblastic metastasis. 80 High PTH levels are associated with increased bone resorption and degradation of the bone matrix and may worsen any skeletal disease secondary to androgen deprivation. The progression of prostate cancer often accelerates once it has spread to the bone which supports the theory that the bone microenvironment may provide stimulating factors for prostate cancer progression. 81 A dangerous positive feedback could be set up in which elevated PTH levels could stimulate osteoclasts, increasing bone resorption and releasing bone derived growth factors that may stimulate progression of prostate cancer. This would, in turn, cause further deposition of calcium in sclerotic metastasis and consequently a further elevation in PTH. 80 There is a risk that bisphosphonate treatment in such patients could result in further falls in serum calcium and further increases in PTH. Increases in serum PTH have been seen in patients treated with bisphosphonates for hypercalcaemia of malignancy, 82 however, pamidronate has been shown to improve the secondary hyperparathyroidism associated with sclerotic metastases. 83 Vitamin D or calcium supplementation may be a wise precaution in some individuals with sclerotic metastases in whom bisphosphonate therapy is being considered.
Preservation of bone mineral density
It is well recognised that androgens have an important role in maintaining skeletal mass in men. Androgen deprivation therapy is the mainstay of treatment for metastatic prostate cancer. Evidence from the MRC immediate versus deferred treatment for advanced prostate cancer trial has shown that early primary androgendeprivation therapy improves outcome in patients with locally advanced, non-metastatic disease. 84 Adjuvant hormone therapy starting at the beginning 85 or end 86 of radiotherapy for locally advanced prostate cancer and continuing for 3 y or more has also been reported to give a significant advantage in local and biochemical disease control with a reduction in the risk of development of metastases at 5 y. There was also a significant survival advantage in the combined modality groups in these trials. Immediate antiandrogen therapy after radical prostatectomy and pelvic lymphadenectomy has also been shown to improve survival and reduces the risk of recurrence in patients with node-positive prostate cancer. 87 Taken together these observations suggest that androgen deprivation therapy for prostate cancer is going to be used earlier in the natural history of the disease and given for longer periods in an increasing number of men. This increased use of hormonal therapy may have important consequences, increasing skeletal complications.
It is now being realised that osteoporosis is an important complication of long-term androgen deprivation therapy. Androgen deprivation therapy has been shown to rapidly accelerate bone loss and decrease bone mineral density in men with prostate cancer. 88, 89 The decrease in bone mineral density is associated with an increase in the risk of fracture. A retrospective study of 224 patients treated with a LHRH agonist and followed up for up to 96 months showed a fracture rate of 9%. 66 A second study in 235 men showed an osteoporotic fracture rate of 13.6% compared to 1.1% in the control group. In this study osteoporotic fractures were much more common than pathological fractures or those due to major trauma. 65 There is consequently an important need for treatment strategies to be developed that do not diminish the antitumourigenic effectiveness of androgen ablation but which minimise skeletal complications.
Two studies have looked at the effect of the aminobisphosphonate, pamidronate, in preventing bone loss during androgen deprivation therapy for prostate cancer. Forty-seven men with locally advanced prostate cancer receiving a GnRH agonist were randomised to receive pamidronate 60 mg i.v. every 12 weeks or placebo. Bone loss in the hip and lumbar spine was prevented by pamidronate in these men. 90 The second study assessed 21 men with metastatic prostate cancer on combined androgen blockade that received a single i.v., infusion of pamidronate 90 mg or placebo. Bone turnover and bone loss was significantly reduced by pamidronate. 91 
Conclusion
There is experimental evidence to suggest that bisphosphonates may have a role in the treatment and prevention of bone metastases secondary to prostate cancer. They have been shown to induce apoptosis in prostate cancer cells and interrupt the metastatic cascade by inhibiting angiogenesis, tumour cell invasion and adhesion to bone. In breast cancer and myeloma, bisphosphonates have a clear supportive role in the treatment of hypercalcaemia and metastatic bone pain and in minimising the development of skeletal complications in patients with established metastases. At present there is a lack of evidence from randomised trials to support the use of bisphosphonates for similar indications in prostate cancer. Osteoporosis and its complications caused by androgen deprivation can be prevented by the use of bisphosphonates which justifies the early use of these agents in patients receiving this type of treatment. 92 The newer, more potent bisphosphonates such as zoledronic acid warrant further study in large, randomised trials to assess safety and efficiency treatment and prevention of bone metastases in prostate cancer.
